Document Detail


Insulin-like growth factors and breast cancer.
MedLine Citation:
PMID:  8746077     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Several years of research have indicated that the insulin-like growth factor (IGF) family of ligands, receptors and binding proteins are expressed in human breast cancer. The ligands are potent mitogens for breast cancer cell lines, and blockade of IGF signaling inhibits tumor growth. The IGFs can be regulated in normal and neoplastic tissue, indicating their important role in proliferation. For example, estrogen, a hormone important in the growth and progression of breast cancer is able to alter expression of IGF ligands, receptors and binding proteins. In addition, recent data now indicate that IGF ligands can also activate estrogen receptor (ER) in a ligand-independent manner. The apparent cross-talk between IGF and ER signaling is especially important to consider since anti-estrogens, such as tamoxifen, are a major modality for the treatment of breast cancer. Recent data suggest that IGFs may also be involved in tamoxifen resistance, through upregulation of the IGF-I receptor. Thus blockade of IGF signaling in combination with tamoxifen may prove to be a beneficial treatment for breast cancer patients.
Authors:
A V Lee; D Yee
Related Documents :
18826367 - Hypophysectomy for prostate cancer: a revival of old knowledge?
22392407 - Comparison of myofibroblasts expression in oral squamous cell carcinoma, verrucous carc...
2311877 - Increased epidermal growth factor receptors in gastric carcinomas.
23849247 - Facial basal cell carcinoma with successive metastases to the neck, thyroid gland and l...
15342447 - Vitamin d, calcium, and mammographic breast densities.
14570527 - Improving quality of life in men with prostate cancer: a randomized controlled trial of...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie     Volume:  49     ISSN:  0753-3322     ISO Abbreviation:  Biomed. Pharmacother.     Publication Date:  1995  
Date Detail:
Created Date:  1996-10-16     Completed Date:  1996-10-16     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8213295     Medline TA:  Biomed Pharmacother     Country:  FRANCE    
Other Details:
Languages:  eng     Pagination:  415-21     Citation Subset:  IM    
Affiliation:
Department of Medicine, University of Texas Health Science Center at San Antonio 78284-7884, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Breast Neoplasms / metabolism*,  pathology
Carrier Proteins / metabolism
Female
Humans
Ligands
Receptors, Estrogen / metabolism
Receptors, Somatomedin / metabolism
Somatomedins / metabolism*
Tumor Cells, Cultured / metabolism
Grant Support
ID/Acronym/Agency:
P01CA30195/CA/NCI NIH HHS; P30CA54174/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Carrier Proteins; 0/Ligands; 0/Receptors, Estrogen; 0/Receptors, Somatomedin; 0/Somatomedins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Estrogen regulated messenger RNAs in human breast cancer cells.
Next Document:  Biological effect of active anti-IFN alpha immunization in HIV-infected patients.